ConductScience.org, home

Paper17519900

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Kamba T and 1 other. Br J Cancer, 2007. Cited by 788 papers, by iCite.

Cite this record

ConductScience Library. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Papers, record 17519900. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17519900

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
PubMed
Journal
Br J Cancer
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
788
iCite
Relative citation ratio, by iCite
18.4
iCite
Revised in PubMed
2024-04-04
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kamba TT
2McDonald DMD M

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Vascular Endothelial Growth Factor AMajor topic
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Benzenesulfonates
Bevacizumab
Hemorrhage
Humans
Indoles
Niacinamide
Phenylurea Compounds
Pyridines
Pyrroles
Signal Transduction
Sorafenib
Sunitinib
Thrombosis
Wound Healing

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 HL024136NHLBI NIH HHSUnited StatesP01HL024136PubMed and NIHNIH RePORTER
R01 CA082923NCI NIH HHSUnited StatesR01CA082923PubMed and NIHNIH RePORTER
HL59157NHLBI NIH HHSUnited StatesR01HL059157PubMed and NIHNIH RePORTER
R01 HL059157NHLBI NIH HHSUnited StatesR01HL059157PubMed and NIHNIH RePORTER
CA082923NCI NIH HHSUnited StatesR01CA082923PubMed and NIHNIH RePORTER
HL24136NHLBI NIH HHSUnited StatesP01HL024136PubMed and NIHNIH RePORTER

Download CSV of grants

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115215160Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.Am J Pathol2004https://conductscience.org/library/papers/15215160PubMed
216784838VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.Biochim Biophys Acta2006https://conductscience.org/library/papers/16784838PubMed
315001532Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels.Circ Res2004https://conductscience.org/library/papers/15001532PubMed
416799557VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.Nat Med2006https://conductscience.org/library/papers/16799557PubMed
515149314The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.Kidney Int2004https://conductscience.org/library/papers/15149314PubMed
616880234Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.Oncologist2006https://conductscience.org/library/papers/16880234PubMed
716126815Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.Am J Physiol Heart Circ Physiol2006https://conductscience.org/library/papers/16126815PubMed
816140331The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.J Surg Res2005https://conductscience.org/library/papers/16140331PubMed
917327610Sunitinib: from rational design to clinical efficacy.J Clin Oncol2007https://conductscience.org/library/papers/17327610PubMed
1016301833Managing patients treated with bevacizumab combination therapy.Oncology2005https://conductscience.org/library/papers/16301833PubMed
1111350732Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.Am J Physiol Cell Physiol2001https://conductscience.org/library/papers/11350732PubMed
129409257Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.Arterioscler Thromb Vasc Biol1997https://conductscience.org/library/papers/9409257PubMed
1317167137Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med2006https://conductscience.org/library/papers/17167137PubMed
1412393615Polycythemia vera: myths, mechanisms, and management.Blood2002https://conductscience.org/library/papers/12393615PubMed
1515175435Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004https://conductscience.org/library/papers/15175435PubMed
1612618525Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.J Clin Invest2003https://conductscience.org/library/papers/12618525PubMed
1717316891Chemotherapy induced reversible posterior leukoencephalopathy syndrome.Lung Cancer2007https://conductscience.org/library/papers/17316891PubMed
1815169807Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol2004https://conductscience.org/library/papers/15169807PubMed
1912086877VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.Cancer Cell2002https://conductscience.org/library/papers/12086877PubMed
2017030665Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.Arch Neurol2006https://conductscience.org/library/papers/17030665PubMed

See all 41 referencesDownload CSV of references

Cited by436

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 788 citations.

PMIDTitleJournalYearIn PapersSource
42958672Integrative network pharmacology and experimental validation to decipher the anti-angiogenic mechanisms of Xuandan Sanjie decotion in adenomyosis.J Tradit Chin Med2026https://conductscience.org/library/papers/42958672PubMed
42861086Neurodevelopmental Disorders in Infants Treated with Anti-VEGF Agents versus Laser Photocoagulation or Cryotherapy for Retinopathy of Prematurity.Ophthalmol Sci2026https://conductscience.org/library/papers/42861086PubMed
42820177Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.Cureus2026https://conductscience.org/library/papers/42820177PubMed
42780318A case of recurrent acute acalculous cholecystitis in a patient with renal cell carcinoma treated with pazopanib and axitinib: case report and literature review.Front Pharmacol2026https://conductscience.org/library/papers/42780318PubMed
42649859The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs).Cancers (Basel)2026https://conductscience.org/library/papers/42649859PubMed
42464367Early-onset duodenal perforation during bevacizumab-containing chemotherapy in a patient with ovarian cancer: a case report.J Pharm Health Care Sci2026https://conductscience.org/library/papers/42464367PubMed
42305612DPPA inhibits melanoma by targeting angiogenesis through activating autocrine IFN-γ-CXCL9/10/11-CXCR3 axis in vascular endothelial cells.iScience2026https://conductscience.org/library/papers/42305612PubMed
42256328A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma.IJU Case Rep2026https://conductscience.org/library/papers/42256328PubMed
42138076Towards precision medicine for brain arteriovenous malformations.J Clin Invest2026https://conductscience.org/library/papers/42138076PubMed
42122227Gastrointestinal and Variceal Bleeding Under Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Evidence from Trials to Real-World Practice.Cancers (Basel)2026https://conductscience.org/library/papers/42122227PubMed
42017533Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma.J Vet Intern Med2026https://conductscience.org/library/papers/42017533PubMed
41939827Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.Front Pharmacol2026https://conductscience.org/library/papers/41939827PubMed
41893767Longitudinal Assessment of an 800 µg Dose of HEBERSaVax in Non-Human Primates over Six Months.Vaccines (Basel)2026https://conductscience.org/library/papers/41893767PubMed
41765886Efficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials.BMC Cancer2026https://conductscience.org/library/papers/41765886PubMed
41716992SHP2 regulates VEGFR2 Y1175/PLCγ signaling to impair tumor endothelial barrier stability.iScience2026https://conductscience.org/library/papers/41716992PubMed
41676232Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection.Oncoscience2026https://conductscience.org/library/papers/41676232PubMed
41602381Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab in hepatocellular carcinoma.Front Oncol2025https://conductscience.org/library/papers/41602381PubMed
41350916Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.J Ovarian Res2025https://conductscience.org/library/papers/41350916PubMed
41257900Cold atmospheric plasma is a promising strategy for treating diabetic retinopathy.J Transl Med2025https://conductscience.org/library/papers/41257900PubMed
41226782A Stable RNA Vaccine Against the Regulatory Peptide Adrenomedullin Reduces Angiogenesis and Tumor Burden in a Subcutaneous Melanoma Model Without Inducing an Immunosuppressive Tumor Microenvironment.Int J Mol Sci2025https://conductscience.org/library/papers/41226782PubMed

See all 436 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17519900

GET https://conductscience.org/api/papers/v1/17519900/references?page=2